NCT06002659 - CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions

B-cell Lymphoma

Interventions

BIOLOGICAL

CAR20(NAP)-T

Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP

DRUG

Cyclophosphamide

pre-conditioning chemotherapy

DRUG

Fludarabine

pre-conditioning chemotherapy

Trial Locations (2)

ACTIVE_NOT_RECRUITING

Karolinska University Hospital, Stockholm

RECRUITING

Uppsala University Hospital, Uppsala